Advancing Alzheimer's Disease Diagnosis Using VGG19 and XGBoost: A Neuroimaging-Based Method

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that currently affects over 55 million individuals worldwide. Conventional diagnostic approaches often rely on subjective clinical assessments and isolated biomarkers, limiting their accuracy and early-stage effectiveness. With the rising global burden of AD, there is an urgent need for objective, automated tools that enhance diagnostic precision using neuroimaging data.

This study proposes a novel diagnostic framework combining a fine-tuned VGG19 deep convolutional neural network with an eXtreme Gradient Boosting (XGBoost) classifier. The model was trained and validated on the OASIS MRI dataset (Dataset 2), which was manually balanced to ensure equitable class representation across the four AD stages. The VGG19 model was pre-trained on ImageNet and fine-tuned by unfreezing its last ten layers. Data augmentation strategies, including random rotation and zoom, were applied to improve generalization. Extracted features were classified using XGBoost, incorporating class weighting, early stopping, and adaptive learning. Model performance was evaluated using accuracy, precision, recall, F1-score, and ROC-AUC.

The proposed VGG19-XGBoost model achieved a test accuracy of 99.6%, with an average precision of 1.00, a recall of 0.99, and an F1-score of 0.99 on the balanced OASIS dataset. ROC curves indicated high separability across AD stages, confirming strong discriminatory power and robustness in classification.

The integration of deep feature extraction with ensemble learning demonstrated substantial improvement over conventional single-model approaches. The hybrid model effectively mitigated issues of class imbalance and overfitting, offering stable performance across all dementia stages. These findings suggest the method's practical viability for clinical decision support in early AD diagnosis.

This study presents a high-performing, automated diagnostic tool for Alzheimer's disease based on neuroimaging. The VGG19-XGBoost hybrid architecture demonstrates exceptional accuracy and robustness, underscoring its potential for real-world applications. Future work will focus on integrating multimodal data and validating the model on larger and more diverse populations to enhance clinical utility and generalizability.